Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Registration Number
- NCT04626479
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first line (1L) clear cell renal cell carcinoma (ccRCC).
This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 400
- Has a histologically confirmed diagnosis of locally advanced/metastatic ccRCC
- Has received no prior systemic therapy for advanced RCC; prior neoadjuvant/adjuvant therapy for RCC is acceptable if completed ≥12 months before randomization/allocation.
- Is able to swallow oral medication
- Has adequate organ function
- Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks before randomization/allocation
- Has resolution of toxic effects of the most recent prior therapy to ≤Grade 1
- Has adequately controlled blood pressure (BP ≤150/90 mm Hg) with no change in hypertensive medications within 1 week before randomization/allocation
- Male participants are abstinent from heterosexual intercourse or agree to use contraception during treatment with and for at least 7 days after the last dose of lenvatinib and /or belzutifan; 7 days after lenvatinib and/or belzutifan is stopped, if the participant is only receiving pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab or a combination of the aforementioned drugs, no contraception is needed
- Female participants must not be pregnant and not be a woman of childbearing potential (WOCBP) or is a WOCBP abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 120 days after the last dose of pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab for 30 days after the last dose of lenvatinib or belzutifan, whichever occurs last and must abstain from breastfeeding during the study intervention period and for at least 120 days after study intervention
- Has urine protein ≥1 g/24 hours and has any of the following: (a) a pulse oximeter reading <92% at rest, or (b) requires intermittent supplemental oxygen, or (c) requires chronic supplemental oxygen (d) active hemoptysis within 3 weeks prior to the first dose of study intervention
- Has clinically significant cardiovascular disease within 12 months from the first dose of study intervention administration
- Has had major surgery within 3 weeks before first dose of study interventions
- Has a history of lung disease
- Has a history of inflammatory bowel disease
- Has preexisting gastrointestinal (GI) or non-GI fistula
- Has malabsorption due to prior GI surgery or disease
- Has received prior radiotherapy within 2 weeks of start of study intervention
- Has received a live or live attenuated vaccine within 30 days before the first dose of study drug; killed vaccines are allowed
- Has received more than 4 previous systemic anticancer treatment regimens
- Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active autoimmune disease that has required systemic treatment in the past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed
- Has an active infection requiring systemic therapy
- Has a known history of human immunodeficiency virus (HIV) infection
- Has a known history of Hepatitis B
- Has had an allogenic tissue/solid organ transplant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pembrolizumab + Belzutifan + Lenvatinib Lenvatinib Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~2 years). Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation. Coformulation Pembrolizumab/Quavonlimab + Lenvatinib Lenvatinib Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to \~2 years). Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation. Coformulation Favezelimab/Pembrolizumab+ Lenvatinib Favezelimab/Pembrolizumab Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) PLUS lenvatinib 20 mg. Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation. Coformulation Favezelimab/Pembrolizumab+ Lenvatinib Lenvatinib Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) PLUS lenvatinib 20 mg. Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation. Pembrolizumab + Belzutifan + Lenvatinib Pembrolizumab Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~2 years). Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation. Pembrolizumab + Belzutifan + Lenvatinib Belzutifan Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~2 years). Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation. Pembrolizumab + Lenvatinib Pembrolizumab Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~ 2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation. Pembrolizumab + Lenvatinib Lenvatinib Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~ 2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation. Coformulation Vibostolimab/Pembrolizumab+Belzutifan Belzutifan Participants will receive vibostolimab/pembrolizumab (coformulation of 200 mg vibostolimab and pembrolizumab 200 mg). Vibostolimab/pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Belzutifan will be administered orally QD until progressive disease or discontinuation. Coformulation Vibostolimab/Pembrolizumab+Belzutifan Vibostolimab/Pembrolizumab Participants will receive vibostolimab/pembrolizumab (coformulation of 200 mg vibostolimab and pembrolizumab 200 mg). Vibostolimab/pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Belzutifan will be administered orally QD until progressive disease or discontinuation. Coformulation Pembrolizumab/Quavonlimab + Lenvatinib Pembrolizumab/Quavonlimab Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to \~2 years). Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
- Primary Outcome Measures
Name Time Method Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs) Up to ~21 days DLTs are defined as one or more of the following toxicities: (1) grade (gr) 4 nonhematologic toxicity (2) gr 4 hematologic toxicity lasting \>7 days OR gr 4 platelet count decreased of any duration OR gr 3 platelet count decreased if associated with bleeding (3) gr 3 nonhematologic toxicity except gr 3 fatigue (lasting ≤3 days), diarrhea, nausea, vomiting or rash without standard of care (4) gr 3 or 4 nonhematologic abnormality if medical intervention is required or if it leads to hospitalization or persists for \>1 week (5) gr 3 or 4 febrile neutropenia (6) gr 3 or 4 alanine aminotransferase, aspartate aminotransferase and/or bilirubin laboratory value (7) treatment related adverse event (AE) causing study intervention discontinuation during the first 21 days (8) treatment related AE causing intervention administration delay for \>14 days during the first 21 days (9) gr 5 toxicity. The number of participants who experience one or more DLTs in the safety lead-in phase will be presented.
Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs) Up to ~21 days An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs in the safety lead-in phase will be presented.
Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AE Up to ~21 days An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE in the safety lead-in phase will be presented.
Efficacy Phase: Number of participants who experience one or more DLTs Up to ~21 days DLTs are defined as one or more of the following toxicities: (1) grade (gr) 4 nonhematologic toxicity (2) gr 4 hematologic toxicity lasting \>7 days OR gr 4 platelet count decreased of any duration OR gr 3 platelet count decreased if associated with bleeding (3) gr 3 nonhematologic toxicity except gr 3 fatigue (lasting ≤3 days), diarrhea, nausea, vomiting or rash without standard of care (4) gr 3 or 4 nonhematologic abnormality if medical intervention is required or if it leads to hospitalization or persists for \>1 week (5) gr 3 or 4 febrile neutropenia (6) gr 3 or 4 alanine aminotransferase, aspartate aminotransferase and/or bilirubin laboratory value (7) treatment related adverse event (AE) causing study intervention discontinuation during the first 21 days (8) treatment related AE causing intervention administration delay for \>14 days during the first 21 days (9) gr 5 toxicity. The number of participants who experience one or more DLTs in the efficacy phase will be presented.
Efficacy Phase: Number of participants who discontinue study treatment due to an AE Up to ~43 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE in the efficacy phase will be presented.
Efficacy Phase: Number of participants who experience one or more AEs Up to ~43 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs in the efficacy phase will be presented.
Efficacy Phase: Objective response rate (ORR) Up to ~43 months ORR is defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
- Secondary Outcome Measures
Name Time Method Efficacy Phase: Duration of response (DOR) Up to ~43 months For participants in the analysis population who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR is defined as the time from first documented evidence of CR or PR until progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 by BICR.
Efficacy Phase: Overall survival (OS) Up to ~43 months OS is defined as the time from randomization to death due to any cause.
Efficacy Phase: Clinical benefit rate (CBR) Up to ~43 months CBR is defined as the percentage of participants who have achieved CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease) of ≥6 months. Responses are according to RECIST 1.1 by BICR.
Efficacy Phase: Progression-free survival (PFS) Up to ~43 months PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 by BICR.
Trial Locations
- Locations (55)
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 2402)
🇳🇱Amsterdam, Noord-Holland, Netherlands
CIDO SpA-Oncology ( Site 2106)
🇨🇱Temuco, Araucania, Chile
The Christie NHS Foundation Trust ( Site 1400)
🇬🇧Manchester, United Kingdom
Oncovida ( Site 2107)
🇨🇱Santiago, Region M. De Santiago, Chile
Bradfordhill-Clinical Area ( Site 2101)
🇨🇱Santiago, Region M. De Santiago, Chile
Sourasky Medical Center ( Site 1503)
🇮🇱Tel Aviv, Israel
Samsung Medical Center ( Site 1801)
🇰🇷Seoul, Korea, Republic of
Hospital Universitari Vall d Hebron ( Site 1300)
🇪🇸Barcelona, Cataluna, Spain
FALP-UIDO ( Site 2100)
🇨🇱Santiago, Region M. De Santiago, Chile
Institut Claudius Regaud ( Site 1200)
🇫🇷Toulouse Cedex 9, Haute-Garonne, France
Oncomédica S.A.S ( Site 1904)
🇨🇴Montería, Cordoba, Colombia
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 1900)
🇨🇴Bogota, Distrito Capital De Bogota, Colombia
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1203)
🇫🇷Strasbourg, Alsace, France
Fundación Valle del Lili ( Site 1901)
🇨🇴Cali, Valle Del Cauca, Colombia
Royal Preston Hospital ( Site 1406)
🇬🇧Preston, Lancashire, United Kingdom
Velindre Cancer Centre Hospital ( Site 1407)
🇬🇧Cardiff, Wales, United Kingdom
University of California at San Francisco ( Site 1008)
🇺🇸San Francisco, California, United States
University of Chicago ( Site 1013)
🇺🇸Chicago, Illinois, United States
Henry Ford Health System ( Site 1014)
🇺🇸Detroit, Michigan, United States
UPMC Cancer Center/Hillman Cancer Center ( Site 1017)
🇺🇸Pittsburgh, Pennsylvania, United States
Duke Cancer Institute ( Site 1015)
🇺🇸Durham, North Carolina, United States
UTSW Medical Center ( Site 1003)
🇺🇸Dallas, Texas, United States
Royal Brisbane and Women s Hospital ( Site 1603)
🇦🇺Herston, Queensland, Australia
Princess Margaret Cancer Centre ( Site 1101)
🇨🇦Toronto, Ontario, Canada
Rabin Medical Center ( Site 1502)
🇮🇱Petah Tiqwa, Israel
Yale-New Haven Hospital-Yale Cancer Center ( Site 1011)
🇺🇸New Haven, Connecticut, United States
Memorial Sloan Kettering Cancer Center ( Site 1002)
🇺🇸New York, New York, United States
Laura and Isaac Perlmutter Cancer Center ( Site 1016)
🇺🇸New York, New York, United States
University of Iowa ( Site 1012)
🇺🇸Iowa City, Iowa, United States
Western Sydney Local Health District ( Site 1601)
🇦🇺Blacktown, New South Wales, Australia
St George Hospital ( Site 1602)
🇦🇺Kogarah, New South Wales, Australia
Jewish General Hospital ( Site 1100)
🇨🇦Montreal, Quebec, Canada
Austin Health ( Site 1600)
🇦🇺Heidelberg, Victoria, Australia
ONCOCENTRO APYS-ACEREY ( Site 2103)
🇨🇱Viña del Mar, Valparaiso, Chile
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1905)
🇨🇴Valledupar, Cesar, Colombia
James Lind Centro de Investigación del Cáncer ( Site 2108)
🇨🇱Temuco, Araucania, Chile
Institut De Cancerologie De Lorraine ( Site 1204)
🇫🇷Vandoeuvre les Nancy, Ain, France
Rambam MC ( Site 1500)
🇮🇱Haifa, Israel
Hadassah Medical Center-Oncology ( Site 1504)
🇮🇱Jerusalem, Israel
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 2301)
🇭🇺Budapest, Pest, Hungary
Sheba Medical Center - Oncology Division ( Site 1501)
🇮🇱Ramat Gan, Israel
Asan Medical Center ( Site 1800)
🇰🇷Songpagu, Seoul, Korea, Republic of
Gustave Roussy ( Site 1202)
🇫🇷Villejuif, Val-de-Marne, France
Severance Hospital ( Site 1802)
🇰🇷Seoul, Korea, Republic of
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 2200
🇵🇱Warszawa, Mazowieckie, Poland
Erasmus Medisch Centrum ( Site 2401)
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Auckland City Hospital ( Site 1700)
🇳🇿Auckland, New Zealand
The Beatson West of Scotland Cancer Centre ( Site 1405)
🇬🇧Glasgow, Glasgow City, United Kingdom
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 2202)
🇵🇱Gdańsk, Pomorskie, Poland
Southampton General Hospital ( Site 1403)
🇬🇧Southampton, England, United Kingdom
Hospital Universitario Ramon y Cajal ( Site 1301)
🇪🇸Madrid, Spain
Leicester Royal Infirmary ( Site 1408)
🇬🇧Leicester, Leicestershire, United Kingdom
Western General Hospital ( Site 1402)
🇬🇧Edinburgh, Midlothian, United Kingdom
Barts Health NHS Trust ( Site 1401)
🇬🇧London, London, City Of, United Kingdom
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2201)
🇵🇱Bydgoszcz, Kujawsko-pomorskie, Poland